dabigatran, rivaroxaban, apixaban, new oral anticoagulants, epidemiological research

Nová orální antikoagulancia jsou v oblasti antikoagulační léčby velkým krokem kupředu. Mají velké množství výhod,ať už se jedná o jejich bezpečnostní profil, či odpadnutí nutnosti monitorace. Pro optimalizaci léčby je ale třeba provádětdalší epidemiologický výzkum v této oblasti.

Purpose: New oral anticoagulants are a big step forward in the area of anticoagulation therapy. They have a large number of benefits, whether it is their security profile or the need for monitoring. However, in order to optimize treatment, epidemiological research should be carried out in this area. Methods: New data from patients from a network of cardiac outpatients were used in the study of new oral anticoagulants. The selection criteria were dabigatran, rivaroxaban and apixaban. Results: Data from 334 patients were analyzed in the study. The male population predominated slightly (55.4%). The most common initial diagnosis for prescribing new oral anticoagulants was 68% of atrial fibrillation. 94% of patients have taken these medicines for a long time. The least adverse effect was apixaban (8 patients), followed by rivaroxaban with 16 patients and most adverse events with dabigatran in 18 patients. Conclusion: Based on epidemiological studies, it is possible to characterize a group of patients using new oral anticoagulants and to optimize the treatment of each patient effectively.